Status:
COMPLETED
Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
Lead Sponsor:
Arete Therapeutics
Conditions:
Hypertension
Impaired Glucose Tolerance
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose toleran...
Eligibility Criteria
Inclusion
- mild to moderate hypertension
- naive to antihypertensive medication or on two or less antihypertensive medications
- impaired glucose tolerance
- mild obesity
Exclusion
- Diagnosis of Type 1 or Type 2 diabetes
- History of severe heart failure
- AST, ALT levels more than twice the normal range
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00847899
Start Date
January 1 2009
End Date
November 1 2009
Last Update
November 20 2009
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Arete Investigational site
Mobile, Alabama, United States, 36617
2
Arete Investigational site
Muscle Shoals, Alabama, United States, 35662
3
Arete Investigational site
Anaheim, California, United States, 92801
4
Arete Investigational site
Concord, California, United States, 94520